Home > Sickle Cell Disease > Dosing and Administration
Sickle Cell Disease Dosing and Administration

Dose-dependent Reductions in Liver Iron Concentration Demonstrated at 1 Year

EXJADE Delivers Dose-dependent Reductions in Liver Iron Concentration1
Change in Liver Iron Concentration

Data from a 1-year, open-label phase II trial, evaluating the safety and tolerability of EXJADE. Efficacy was measured by change in liver iron concentration (LIC) using biosusceptometry. Adjusted change (mean + SD) in LIC determined according to assigned treatment category for EXJADE.1

Titrate and monitor to reach chelation goals2

  • The recommended daily starting dose of EXJADE is 20 mg/kg body weight
  • Monitor serum ferritin monthly and assess trends with steady-state levels
  • Titrate EXJADE by steps of 5 mg/kg/day to 10 mg/kg/day every 3 to 6 months based on individual patient's response and therapeutic goals (maintenance or reduction of iron)
  • EXJADE is approved at doses up to 40 mg/kg/day for patients not adequately controlled with doses of 30 mg/kg (eg, serum ferritin levels persistently above 2,500 μg/l and not showing a decreasing trend over time)
  • Doses above 40 mg/kg are not recommended because there is only limited experience with doses above this level
  • Dose reductions, in steps of 5 to 10 mg/kg, should be considered in patients whose serum ferritin levels have reached the target (usually between 500 and 1000 μg/L) in order to maintain serum ferritin levels within the target range
Learn more about monitoring

EXJADE DOSING OPTIONS

Titrate from the recommended starting dose of 20 mg/kg/day based on individual patient′s response and therapeutic goals. Please check the Prescribing Information for your region for details.

Learn more

EXJADE ADMINISTRATION

Help ensure your patients properly take their once-daily oral therapy.

Learn more